FREE DOWNLOAD: 5 Stocks To Buy & Hold Forever
New research report reveals the top 5 stocks to buy & HOLD FOREVER...

...through every wild market swing and through every unknown economic shift in the future.

(It's a quick read.)
Click to download.
John Stephen West, insider at Personalis
John Stephen West Insider Alerts

Get notified the next time John Stephen West buys or sells Personalis stock. Enter your email address below to get our daily insider buying and selling report.

John Stephen West Insider Information

CEO of Personalis
Personalis’ CEO, John West, first became involved in DNA sequencing and DNA sequence interpretation in 1982. In the 1980’s, he led the development of an automated DNA sequencing system based on pattern recognition from autoradiographs, and licensed software from the lab of Roger Staden at MRC Cambridge, UK for sequence assembly and analysis. In the 1990’s Mr. West was General Manager and subsequently President of Princeton Instruments, a company focused on low light scientific imaging. This technology was used in a number of fluorescent automated DNA sequencing developments. In 2001 Mr. West joined then market leader Applied Biosystems as Vice President of Genetic Analysis. He was subsequently promoted to VP, DNA Platforms. While at Applied Biosystems Mr. West’s group introduced the model 3730xl Genetic Analyzer. This product became the mainstay of almost every major genome center in the world.

In 2004, Mr. West moved to be CEO of Solexa Ltd, a venture capital backed UK company focused primarily on single-molecule DNA sequencing. Mr. West realized that the company’s recent acquisition of DNA cluster technology could be transformative. In 2005 he led Solexa’s reverse merger into US-based and Nasdaq-listed Lynx Therapeutics, and led two PIPE financings totaling almost $100M. The company introduced its first system in mid-2006. Mr. West negotiated the January 2007 acquisition of Solexa by Illumina, Inc for approximately $600M, and stayed as VP of the DNA sequencing business there into 2008. During this time, Illumina became the world leader in next generation DNA sequencing.

From 2009 through mid-2011 Mr. West served as CEO of ViaCyte, Inc, a company leveraging stem cell technology to develop a diabetes cell therapy.

In late 2009 Mr. West’s family became the first healthy family of four to be sequenced. Their experience  working with the Stanford team on genome interpretation led to the foundation of Personalis.

Mr. West received a BS and MS engineering degrees from MIT, and earned an MBA from the University of Pennsylvania’s Wharton School of Business.

What is John Stephen West's net worth?

The estimated net worth of John Stephen West is at least $6.82 million as of June 8th, 2021. Mr. West owns 670,520 shares of Personalis stock worth more than $6,819,188 as of January 22nd. This net worth estimate does not reflect any other investments that Mr. West may own. Learn More.

How do I contact John Stephen West?

The corporate mailing address for Mr. West and other Personalis executives is 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025. Personalis can also be reached via phone at (650) 752-1300 and via email at [email protected]

Has John Stephen West been buying or selling shares of Personalis?

During the last ninety days, John Stephen West has sold $416,227.00 in shares of Personalis stock. Most recently, John Stephen West sold 35,484 shares of the business's stock in a transaction on Tuesday, January 18th. The shares were sold at an average price of $11.73, for a transaction totalling $416,227.32.

Who are Personalis' active insiders?

Personalis' insider roster includes Richard Chen (Insider), Aaron Tachibana (CFO), and John West (CEO).

Are insiders buying or selling shares of Personalis?

In the last year, insiders at the sold shares 26 times. They sold a total of 632,398 shares worth more than $11,807,325.20. The most recent insider tranaction occured on January, 18th when CEO John Stephen West sold 35,484 shares worth more than $416,227.32. Insiders at Personalis own 7.5 % of the company.

Information on this page was last updated on 1/18/2022.

John Stephen West Insider Trading History at Personalis

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/18/2022Sell35,484$11.73$416,227.32View SEC Filing Icon  
12/16/2021Sell97,268$13.42$1,305,336.56View SEC Filing Icon  
11/30/2021Sell100,000$13.65$1,365,000.00View SEC Filing Icon  
11/17/2021Sell2,348$17.04$40,009.92View SEC Filing Icon  
10/12/2021Sell100,000$19.33$1,933,000.00View SEC Filing Icon  
7/8/2021Sell110,000$22.54$2,479,400.00View SEC Filing Icon  
6/8/2021Sell110,000$22.43$2,467,300.00670,520View SEC Filing Icon  
See Full Table

John Stephen West Buying and Selling Activity at Personalis

This chart shows John Stephen West's buying and selling at Personalis by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Personalis Company Overview

Personalis logo
Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.
Read More

Today's Range

Now: $10.17
Low: $10.15
High: $11.07

50 Day Range

MA: $13.57
Low: $10.17
High: $17.34

2 Week Range

Now: $10.17
Low: $10.15
High: $49.29

Volume

772,537 shs

Average Volume

512,474 shs

Market Capitalization

$455.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.55
5 Free Dividend Stocks for 2022
Could these top payout stocks be part of the greatest wealth-creating tool in history?
Learn More.